2,3-二氯-苯磺酸 | 93648-06-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二氯-苯磺酸
• 中文别名: 2,3-二氯苯磺酸
• 英文名称: 2,3-dichloro-benzenesulfonic acid
• 英文别名: 2,3-Dichlor-benzolsulfonsaeure；2,3-dichlorobenzenesulfonic Acid
• CAS: 93648-06-7
• 化学式: C₆H₄Cl₂O₃S
• 分子量: 227.068
• InChiKey: ZGZXYZZHXXTTJN-UHFFFAOYSA-N

物化性质

• 密度：
  1.668

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  邻二氯苯 在 硫酸 、 汞 作用下， 生成 2,3-二氯-苯磺酸 、 3,4-二氯苯磺酸
  参考文献：
  名称：

  Lauer, Journal fur praktische Chemie (Leipzig 1954), 1933, vol. <2> 138, p. 81,86, 89, 90

  摘要：

  DOI：

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE
  申请人：Okamoto Kuniaki

  公开号：US20120130107A1

  公开（公告）日：2012-05-24

  Object To provide a method for producing a bis-quaternary ammonium salt efficiently and a novel synthetic intermediate thereof. Solution The present invention relates to a method for producing a bis-quaternary ammonium salt represented by a general formula [3] which comprises reacting a disulfonic acid ester represented by a general formula [1] (in the formula, definitions of two R 1 's and T are as described in claim 1 ) with a tertiary amine represented by a general formula [2] (in the formula, definitions of R 3 to R 5 are as described in claim 1 ), and a disulfonic acid ester represented by a general formula [1′] (in the formula, two R 16 's represent independently a halogen atom or a C1-C3 fluoroalkyl group, and two m's represent independently an integer of 1 to 5).

  提供一种高效生产双季铵盐和其新型合成中间体的方法。本发明涉及一种生产由通用式[3]表示的双季铵盐的方法，包括将由通用式[1]表示的二磺酸酯（在该式中，两个R1和T的定义如权利要求1中所述）与由通用式[2]表示的三级胺（在该式中，R3到R5的定义如权利要求1中所述）以及由通用式[1']表示的二磺酸酯（在该式中，两个R16独立表示卤原子或C1-C3氟烷基，两个m独立表示1至5的整数）反应。
• [EN] DACLATASVIR FREE BASE AND PROCESS FOR THE PREPARATION THEREOF<br/>[FR] BASE LIBRE DE DACLATASVIR ET PROCÉDÉ POUR LA PRÉPARATION DE CELLE-CI
  申请人：LAURUS LABS PRIVATE LTD

  公开号：WO2017021904A1

  公开（公告）日：2017-02-09

  The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparation and purification of daclatasvir dihydrochloride.

  本发明涉及达克拉他韦的游离碱，其制备方法，以及将其转化为达克拉他韦的药用可接受盐的方法。本发明还涉及达克拉他韦二盐的制备和纯化方法。
• [EN] PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS<br/>[FR] PYRROLOPYRIMIDINES UTILISEES COMME INHIBITEURS DE TYROSINE KINASES
  申请人：BASF AG

  公开号：WO2001072751A1

  公开（公告）日：2001-10-04

  Chemical compounds having structural formula (I), and physiologically acceptable salts and metabolites thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases, whose activity is inhibited by these chemical compounds, are involved in immunologic, hyperproliferative, or angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyper proliferative disorders, rheumatiod arthritis, disorders of the immune system, transplant rejections and ifplammatory disorders.

  具有结构式（I）的化合物及其生理上可接受的盐和代谢物是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的多种激酶参与免疫、高增殖或血管生成过程。因此，这些化合物可以缓解血管生成或内皮细胞过度增殖是疾病状态的情况。这些化合物可用于治疗癌症和高增殖性疾病、类风湿性关节炎、免疫系统疾病、移植排斥和炎症性疾病。
• Compositions for use in golf balls
  申请人：Bulpett A. David

  公开号：US20050245652A1

  公开（公告）日：2005-11-03

  A golf ball comprises a core, an outer cover layer, and, optionally, an intermediate layer disposed between the core and the outer cover layer. The outer cover layer may comprise a polyurethane or polyurea composition. At least one portion of the golf ball comprises a composition that enhances physical properties and/or performance characteristics (e.g., coefficient of restitution) of the golf ball. Preferably, the coefficient of restitution of the core is 0.8 or greater.

  高尔夫球由内核、外覆盖层和可选的中间层组成，外覆盖层可以包括聚氨酯或聚脲组成。高尔夫球的至少一部分包含一种增强物理特性和/或性能特征（例如反弹系数）的组合物。最好，内核的反弹系数为0.8或更高。